Discover investment opportunities in Genome Editing Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Genome Editing Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Genome Editing Stocks using our Smart AI Filter.
6 stocks found for "Genome Editing Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
2.51 | ±100.0% | -1.1 | 0.00% | |||
1.92 | ±68.6% | -1.9 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
1.98 | ±100.0% | -2.4 | 0.00% | |||
1.17 | ±76.9% | -0.7 | 0.00% | |||
1.39 | ±92.0% | -3.9 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How has CRISPR Therapeutics (CRSP) performed relative to other genome editing stocks?
A: CRISPR Therapeutics (CRSP) is a leading company in the genome editing space. Historically, it has demonstrated strong performance in both clinical advancements and market recognition, often mirroring or exceeding industry dynamics. Investors should consider its role in cutting-edge CRISPR technology compared to peers like EDIT or NTLA.
Q: What is the investment appeal of Beam Therapeutics (BEAM) in the genome editing sector?
A: Beam Therapeutics (BEAM) focuses on base editing, an innovative approach within genome editing. This method offers precision that may interest investors looking for advanced solutions beyond traditional CRISPR technology. Its specialist focus can present unique growth opportunities in the field.
Q: Are gene editing stocks like Sangamo Therapeutics (SGMO) suitable for growth-focused investors?
A: Sangamo Therapeutics (SGMO) invests heavily in gene therapy and genome editing, areas poised for significant growth. However, the growth trajectory is unpredictable, with market dynamics impacting performance. Investors seeking growth should consider potential volatility along with sector-specific innovation.
Q: What economic cycles influence Intellia Therapeutics (NTLA) stock performance?
A: Intellia Therapeutics (NTLA) may be less sensitive to typical economic cycles due to its focus on biotechnology and healthcare, often considered non-cyclical. However, regulatory developments and R&D milestones notably influence its stock performance, requiring careful monitoring by investors.
Q: How do ESG factors affect investments in Editas Medicine (EDIT)?
A: Editas Medicine (EDIT) is subject to ESG scrutiny, particularly in ethical considerations of genome editing. Investors emphasizing ESG may consider the company’s ethical frameworks and policies on genetic innovation, which can impact long-term sustainability and investor perception.
Q: What sector-specific risks should be considered with Verve Therapeutics (VERV) investments?
A: Verve Therapeutics (VERV) focuses on cardiovascular disease through gene editing, presenting unique risks such as clinical trial outcomes and sector competitiveness in biotech innovations. Investors should assess these alongside regulatory risk, which is inherent in the healthcare sector.